



Commenced broad and extensive collaboration to jointly commercialize pharmaceuticals based on Goryo technology

Signed a comprehensive collaboration agreement to develop and commercialize drug candidates in the therapeutic field as well as in the diagnostic field

Goryo Chemical Co., Ltd. (head office: Sapporo, Japan; CEO and Representative Director: Ken-ichi Maruyama; hereinafter referred to as "Goryo") and Solasia Pharma Co., Ltd. (head office: Tokyo, Japan; President and CEO: Yoshihiro Arai, hereinafter referred to as "Solasia") have reached an agreement to explore opportunities to jointly develop and commercialize pharmaceutical products, based on Goryo's technologies and assets, which include the development of candidate drugs for therapeutic use as well as for in-vitro and in-vivo diagnostic use. The agreement is signed and becomes effective on July 13th, 2023.

The agreement provides Goryo and Solasia with a comprehensive framework to collaborate and explore opportunities to jointly develop and commercialize Goryo's pharmaceutical products. It includes the development of GCP-006, the navigation drug for the breast cancer, for which an NDA (New Drug Approval) application has been filed in Japan (note 1), and other navigation drugs. The collaboration can be extended to include the development of Goryo's drug candidates for therapeutic use as well. In addition to the development of navigation drugs for cancer surgery using functional fluorescent probes, Goryo is also engaged in developing new drug candidates for therapeutic use by leveraging the knowledge and know-how obtained and accumulated from the development of functional fluorescent probes in the past.

(Note 1) As announced in the press release dated April 5, 2023, an NDA application has been filed with the regulatory authority, Ministry of Health, Labor and Welfare in Japan.

1. Details of the agreement for comprehensive collaboration

Detailed information other than those described in this press release are confidential and will not be disclosed.

2. Overview of the companies

Name	Goryo Chemical Co., Ltd.
Head office address	35-100 Kita 8-jo Nishi 18-chome, Chuo-ku, Sapporo, Hokkaido, Japan
Representative	Representative Director and CEO: Ken-ichi Maruyama
Established	July 2010
Business and its scope	Manufacture and sale of functional fluorescent probes, contract synthesis, development of navigational drugs using functional fluorescent probes for cancer surgery

Company Name	Solasia Pharma K.K.
Head office address	Sumitomo Fudosan Shibakoen Tower 4F, 2-11-1 Shibakoen, Minato-ku, Tokyo, Japan
Representative	Representative Director Yoshihiro Arai
Established	January 2006
Business and its scope	Development, sales, import/export, etc. of pharmaceuticals and medical devices

3. (Reference) Goryo Chemical Co., Ltd.

Goryo has developed and manufactured the world's first product that selectively illuminates the cancer tissue only a few minutes after a fluorescent probe is sprayed on a human tissue fragment. Based upon this technology, Goryo has developed reagent businesses for research use and has been expanding its business scope to include developing navigation drugs for both in-vitro and in-

vivo diagnostic use to be utilized during surgical procedures, mainly for cancer. The navigation drug, also known as "Fluorescent Image-Guided Surgery" (surgical support using fluorescent imaging (Note 2)), is a new and emerging mode of technology that is increasingly attracting attention for research and clinical use.

Goryo's focus thus far has mainly been on the development of navigation drugs that can be applied in surgery and/or medical checkups for various types of cancers, in order to allow early detection and treatment, prevent recurrence and promote early recovery post-surgery. In addition to developing navigation drugs for cancer, Goryo's unique fluorescent technology can also be applied to the early detection and treatment of non-cancerous diseases. The fluorescent probe to detect calpain enzyme, currently being developed by Goryo, is a good example of the new endeavor by the company to expand its scope of R&D activities into new target fields other than cancer. To this end, Goryo has formalized a global license agreement for the ophthalmology area with Senju Pharmaceutical, Inc. on April 5, 2023 (refer to the press-release of the same date). In addition to the development of candidates for diagnostic use, Goryo is also engaged in developing new drug candidates for therapeutic use, by making the best use of its knowledge and know-how accumulated through developing fluorescent probe technology.

(Note 2) Fluorescence imaging: A technique that enables observation of the localization and movement of cells, specific proteins, etc. by shining a laser or other light on various fluorescent dyes and fluorescent proteins.

Contact:

Takuma Nakatsuka

Goryo Chemical Co., Ltd.

Email: nakatsuka@goryochemical.com